Results 1 to 10 of about 28,079 (244)

Pharmacology of HIV integrase inhibitors. [PDF]

Curr Opin HIV AIDS, 2012
The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).
Adams JL, Greener BN, Kashuba AD.
europepmc   +7 more sources

HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses. [PDF]

mBio, 2014
The catalytic site of the HIV integrase is contained within an RNase H-like fold, and numerous drugs have been developed that bind to this site and inhibit its activity.
Yan Z, Bryant KF, Gregory SM, Angelova M, Dreyfus DH, Zhao XZ, Coen DM, Burke TR, Knipe DM.   +8 more
europepmc   +6 more sources

Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis [PDF]

PLoS ONE, 2013
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
A Talbot, AJ Viera, Annemarie M. J. Wensing, AR Zolopa, Axel Fun, B Grinsztejn, B Taiwo, B Young, C Cohen, C Garrido, D McMahon, D Moher, DK Owens, DV Cordery, E DeJesus, E Martinez, E Vispo, EM Gardner, F Caby, F Canducci, F Smith, H Byakwaga, H Hatano, J Reynes, J van Lunzen, JJ Eron, JJ Eron Jr, JK Rockstroh, JL Lennox, JL Lennox, JM Gatell, JM Molina, JR Santos, L Van Wesenbeeck, L Wittkop, Linos Vandekerckhove, Luis Menéndez-Arias, M Harris, M Markowitz, M Markowitz, MA Thompson, MJ Buzon, MJ Kozal, Monique Nijhuis, N Mantel, Nele Brusselaers, O Goethals, PE Sax, Peter Messiaen, R Qaqish, R Relevo, RT Gandhi, RT Gandhi, RT Steigbigel, RT Steigbigel, S Gallien, S Nozza, V Dahl, W Towner, Y Yazdanpanah   +59 more
core   +9 more sources

Update on Adverse Effects of HIV Integrase Inhibitors. [PDF]

Curr Treat Options Infect Dis, 2019
Abstract Purpose of review The goal of this paper is to provide an up-to-date review of adverse events related to the class of integrase strand transfer inhibitors (INSTIs), which became the class of choice in few years.
Kolakowska A, Maresca AF, Collins IJ, Cailhol J.   +3 more
europepmc   +6 more sources

Resistance to HIV integrase inhibitors

Current Opinion in HIV and AIDS, 2012
HIV integrase inhibitors are potent antiretroviral drugs that efficiently decrease viral load in patients. Emergence of resistance mutations against this new class of drugs represents a threat to their long-term efficacy. The purpose of this review is to provide new information about the most recent mutations identified and other mutations that confer ...
Peter K. Quashie, Mark A. Wainberg, Thibault Mesplède   +2 more
  +12 more sources

Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use. [PDF]

HIV Med
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are the mainstay of treatment in adults and children living with HIV. Weight gain has been associated with INSTI use in adults; however, less data exist on its effects on younger patients.
Pincus KJ, Faridi N, Ryscavage PA, Seung H, Parbuoni KA, Grant M, Pandit NS.   +6 more
europepmc   +2 more sources

Treatment of HIV Infections with HIV Integrase Inhibitors. [PDF]

ACS Med Chem Lett, 2017
Abdel-Magid AF.
europepmc   +5 more sources

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel, Borch, Alexandra, De Scheerder, Marie-Angélique, De Spiegelaere, Ward, Koenig, Renate, Malatinková, Eva, Melkova, Zora, Vandekerckhove, Linos   +7 more
core   +1 more source

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya [PDF]

, 2020
BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients.
Lihana Raphael, Ngugi Caroline, Nyamache Anthony, Nyerere Andrew, Sepha, Mabeya   +4 more
core   +2 more sources